Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.
| Autor: | Paluri RK; Department of Hematology-Oncology, Atrium Health Wake Forest Baptist, Winston-Salem, NC, United States., Pulipati Y; Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, United States., Regalla DKR; Department of Hospital Medicine, OSF Saint Anthony Medical Center, Rockford, IL, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Oncology reviews [Oncol Rev] 2023 Nov 17; Vol. 17, pp. 11456. Date of Electronic Publication: 2023 Nov 17 (Print Publication: 2023). |
| DOI: | 10.3389/or.2023.11456 |
| Abstrakt: | Immune checkpoint inhibitors (ICIs) have reshaped and have become a well-established treatment modality for multiple advanced-stage malignancies. ICIs block the immune system regulatory checkpoints, namely CTLA-4 and PD-1/PDL1, which provokes excess immune response against self-antigens. Immune modulation with ICIs can result in diverse immune-related adverse events targeting organ systems. Several cases of ICI-related cardiotoxicity were reported, while the actual incidence was likely underestimated due to heterogeneous clinical presentation. These include, but are not limited to, myocarditis, pericarditis, atherosclerosis, and arrhythmia. EKG, Troponin, Echocardiogram (TTE), and Cardiac MRI (CMRI) are indispensable diagnostic tools to aid in the management of cardiac adverse effects. Herein, we review the ICI-mediated cardiovascular adverse events, diagnosis, treatment strategies, and reintroduction of ICIs post-cardiotoxicity. Competing Interests: RP is a consultant and adivisor for Exelixis, Ipsen and Seagen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Paluri, Pulipati and Regalla.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|